pcDNA3.1-SARS2-Spike Citations (52)

Originally described in: Structural basis of receptor recognition by SARS-CoV-2.
Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F Nature. 2020 Mar 30. pii: 10.1038/s41586-020-2179-y. doi: 10.1038/s41586-020-2179-y. PubMed Journal

---

Articles Citing pcDNA3.1-SARS2-Spike

Articles
The D614G mutation in SARS-CoV-2 Spike increases transduction of multiple human cell types. Daniloski Z, Guo X, Sanjana NE. bioRxiv. 2020 Jun 15. doi: 10.1101/2020.06.14.151357. PubMed
Infection of Brain Organoids and 2D Cortical Neurons with SARS-CoV-2 Pseudovirus. Yi SA, Nam KH, Yun J, Gim D, Joe D, Kim YH, Kim HJ, Han JW, Lee J. Viruses. 2020 Sep 8;12(9). pii: v12091004. doi: 10.3390/v12091004. PubMed
Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions. Chatterjee P, Ponnapati M, Kramme C, Plesa AM, Church GM, Jacobson JM. Commun Biol. 2020 Nov 23;3(1):715. doi: 10.1038/s42003-020-01470-7. PubMed
The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. Daniloski Z, Jordan TX, Ilmain JK, Guo X, Bhabha G, tenOever BR, Sanjana NE. Elife. 2021 Feb 11;10. pii: 65365. doi: 10.7554/eLife.65365. PubMed Associated Plasmids pcDNA3.1-SARS2-Spike-D614G
Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma. Tso FY, Lidenge SJ, Poppe LK, Pena PB, Privatt SR, Bennett SJ, Ngowi JR, Mwaiselage J, Belshan M, Siedlik JA, Raine MA, Ochoa JB, Garcia-Diaz J, Nossaman B, Buckner L, Roberts WM, Dean MJ, Ochoa AC, West JT, Wood C. PLoS One. 2021 Mar 4;16(3):e0247640. doi: 10.1371/journal.pone.0247640. eCollection 2021. PubMed
A weak COPI binding motif in the cytoplasmic tail of SARS-CoV-2 spike glycoprotein is necessary for its cleavage, glycosylation, and localization. Jennings BC, Kornfeld S, Doray B. FEBS Lett. 2021 Jul;595(13):1758-1767. doi: 10.1002/1873-3468.14109. Epub 2021 May 26. PubMed
Platycodin D, a natural component of Platycodon grandiflorum, prevents both lysosome- and TMPRSS2-driven SARS-CoV-2 infection by hindering membrane fusion. Kim TY, Jeon S, Jang Y, Gotina L, Won J, Ju YH, Kim S, Jang MW, Won W, Park MG, Pae AN, Han S, Kim S, Lee CJ. Exp Mol Med. 2021 May;53(5):956-972. doi: 10.1038/s12276-021-00624-9. Epub 2021 May 25. PubMed
Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. Higuchi Y, Suzuki T, Arimori T, Ikemura N, Mihara E, Kirita Y, Ohgitani E, Mazda O, Motooka D, Nakamura S, Sakai Y, Itoh Y, Sugihara F, Matsuura Y, Matoba S, Okamoto T, Takagi J, Hoshino A. Nat Commun. 2021 Jun 21;12(1):3802. doi: 10.1038/s41467-021-24013-y. PubMed
Heparan Sulfate Facilitates Spike Protein-Mediated SARS-CoV-2 Host Cell Invasion and Contributes to Increased Infection of SARS-CoV-2 G614 Mutant and in Lung Cancer. Yue J, Jin W, Yang H, Faulkner J, Song X, Qiu H, Teng M, Azadi P, Zhang F, Linhardt RJ, Wang L. Front Mol Biosci. 2021 Jun 11;8:649575. doi: 10.3389/fmolb.2021.649575. eCollection 2021. PubMed
Environmentally-induced mdig contributes to the severity of COVID-19 through fostering expression of SARS-CoV-2 receptor NRPs and glycan metabolism. Zhang Q, Wadgaonkar P, Xu L, Thakur C, Fu Y, Bi Z, Qiu Y, Almutairy B, Zhang W, Stemmer P, Chen F. Theranostics. 2021 Jul 6;11(16):7970-7983. doi: 10.7150/thno.62138. eCollection 2021. PubMed
CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro. Ma MT, Badeti S, Chen CH, Kim J, Choudhary A, Honnen B, Reichman C, Calianese D, Pinter A, Jiang Q, Shi L, Zhou R, Xu H, Li Q, Gause W, Liu D. Front Immunol. 2021 Jul 23;12:652223. doi: 10.3389/fimmu.2021.652223. eCollection 2021. PubMed
Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor. Liu J, Bodnar BH, Meng F, Khan AI, Wang X, Saribas S, Wang T, Lohani SC, Wang P, Wei Z, Luo J, Zhou L, Wu J, Luo G, Li Q, Hu W, Ho W. Cell Biosci. 2021 Aug 30;11(1):168. doi: 10.1186/s13578-021-00680-8. PubMed
Application of pseudotyped virus particles to monitor Ebola virus and SARS-CoV-2 viral entry in human cell lines. Eichler M, Aksi E, Pfeilschifter J, Imre G. STAR Protoc. 2021 Dec 17;2(4):100818. doi: 10.1016/j.xpro.2021.100818. Epub 2021 Aug 27. PubMed
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. Conforti A, Marra E, Palombo F, Roscilli G, Rava M, Fumagalli V, Muzi A, Maffei M, Luberto L, Lione L, Salvatori E, Compagnone M, Pinto E, Pavoni E, Bucci F, Vitagliano G, Stoppoloni D, Pacello ML, Cappelletti M, Ferrara FF, D'Acunto E, Chiarini V, Arriga R, Nyska A, Di Lucia P, Marotta D, Bono E, Giustini L, Sala E, Perucchini C, Paterson J, Ryan KA, Challis AR, Matusali G, Colavita F, Caselli G, Criscuolo E, Clementi N, Mancini N, Gross R, Seidel A, Wettstein L, Munch J, Donnici L, Conti M, De Francesco R, Kuka M, Ciliberto G, Castilletti C, Capobianchi MR, Ippolito G, Guidotti LG, Rovati L, Iannacone M, Aurisicchio L. Mol Ther. 2021 Sep 20. pii: S1525-0016(21)00466-4. doi: 10.1016/j.ymthe.2021.09.011. PubMed Associated Plasmids pcDNA3.1_ spike_del19
Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern. Carter-Timofte ME, Arulanandam R, Kurmasheva N, Fu K, Laroche G, Taha Z, van der Horst D, Cassin L, van der Sluis RM, Palermo E, Di Carlo D, Jacobs D, Maznyi G, Azad T, Singaravelu R, Ren F, Hansen AL, Idorn M, Holm CK, Jakobsen MR, van Grevenynghe J, Hiscott J, Paludan SR, Bell JC, Seguin J, Sabourin LA, Cote M, Diallo JS, Alain T, Olagnier D. ACS Infect Dis. 2021 Nov 12;7(11):3034-3051. doi: 10.1021/acsinfecdis.1c00278. Epub 2021 Oct 18. PubMed
Combustible and Electronic Cigarette Exposures Increase ACE2 Activity and SARS-CoV-2 Spike Binding. Ghosh A, Girish V, Yuan ML, Coakley RD, Wrennall JA, Alexis NE, Sausville EL, Vasudevan A, Chait AR, Sheltzer JM, Tarran R. Am J Respir Crit Care Med. 2022 Jan 1;205(1):129-133. doi: 10.1164/rccm.202106-1377LE. PubMed
Disulfide Bonds Play a Critical Role in the Structure and Function of the Receptor-binding Domain of the SARS-CoV-2 Spike Antigen. Grishin AM, Dolgova NV, Landreth S, Fisette O, Pickering IJ, George GN, Falzarano D, Cygler M. J Mol Biol. 2022 Jan 30;434(2):167357. doi: 10.1016/j.jmb.2021.167357. Epub 2021 Nov 12. PubMed
Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography. Ubah OC, Lake EW, Gunaratne GS, Gallant JP, Fernie M, Robertson AJ, Marchant JS, Bold TD, Langlois RA, Matchett WE, Thiede JM, Shi K, Yin L, Moeller NH, Banerjee S, Ferguson L, Kovaleva M, Porter AJ, Aihara H, LeBeau AM, Barelle CJ. Nat Commun. 2021 Dec 16;12(1):7325. doi: 10.1038/s41467-021-27611-y. PubMed
SARS-CoV-2 Spike Antagonizes Innate Antiviral Immunity by Targeting Interferon Regulatory Factor 3. Freitas RS, Crum TF, Parvatiyar K. Front Cell Infect Microbiol. 2022 Jan 10;11:789462. doi: 10.3389/fcimb.2021.789462. eCollection 2021. PubMed
Humoral and Cellular Responses to COVID-19 Vaccines in SARS-CoV-2 Infection-Naive and -Recovered Korean Individuals. Hwang JY, Kim Y, Lee KM, Jang EJ, Woo CH, Hong CU, Choi ST, Xayaheuang S, Jang JG, Ahn JH, Park H. Vaccines (Basel). 2022 Feb 18;10(2). pii: vaccines10020332. doi: 10.3390/vaccines10020332. PubMed
Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models. Yang H, Cao J, Lin X, Yue J, Zieneldien T, Kim J, Wang L, Fang J, Huang RP, Bai Y, Sneed K, Cao C. Viruses. 2022 Feb 22;14(3). pii: v14030449. doi: 10.3390/v14030449. PubMed
Synthetic carbohydrate-binding agents neutralize SARS-CoV-2 by inhibiting binding of the spike protein to ACE2. Francesconi O, Donnici L, Fragai M, Pesce E, Bombaci M, Fasciani A, Manganaro L, Conti M, Grifantini R, De Francesco R, Nativi C, Roelens S. iScience. 2022 May 20;25(5):104239. doi: 10.1016/j.isci.2022.104239. Epub 2022 Apr 11. PubMed
An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo. Ikemura N, Taminishi S, Inaba T, Arimori T, Motooka D, Katoh K, Kirita Y, Higuchi Y, Li S, Suzuki T, Itoh Y, Ozaki Y, Nakamura S, Matoba S, Standley DM, Okamoto T, Takagi J, Hoshino A. Sci Transl Med. 2022 Jun 22;14(650):eabn7737. doi: 10.1126/scitranslmed.abn7737. Epub 2022 Jun 22. PubMed
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. Torres JL, Ozorowski G, Andreano E, Liu H, Copps J, Piccini G, Donnici L, Conti M, Planchais C, Planas D, Manganaro N, Pantano E, Paciello I, Pileri P, Bruel T, Montomoli E, Mouquet H, Schwartz O, Sala C, De Francesco R, Wilson IA, Rappuoli R, Ward AB. Proc Natl Acad Sci U S A. 2022 May 17;119(20):e2120976119. doi: 10.1073/pnas.2120976119. Epub 2022 May 12. PubMed
Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells. Caputo I, Caroccia B, Frasson I, Poggio E, Zamberlan S, Morpurgo M, Seccia TM, Cali T, Brini M, Richter SN, Rossi GP. Int J Mol Sci. 2022 May 4;23(9). pii: ijms23095125. doi: 10.3390/ijms23095125. PubMed
The ORF8 Protein of SARS-CoV-2 Modulates the Spike Protein and Its Implications in Viral Transmission. Chou JM, Tsai JL, Hung JN, Chen IH, Chen ST, Tsai MH. Front Microbiol. 2022 May 19;13:883597. doi: 10.3389/fmicb.2022.883597. eCollection 2022. PubMed
GMI, a protein from Ganoderma microsporum, induces ACE2 degradation to alleviate infection of SARS-CoV-2 Spike-pseudotyped virus. Yeh H, Vo DNK, Lin ZH, Ho HPT, Hua WJ, Qiu WL, Tsai MH, Lin TY. Phytomedicine. 2022 Aug;103:154215. doi: 10.1016/j.phymed.2022.154215. Epub 2022 May 28. PubMed
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations. Favalli A, Favalli EG, Gobbini A, Zagato E, Bombaci M, Maioli G, Pesce E, Donnici L, Gruarin P, Biggioggero M, Curti S, Manganaro L, Marchisio E, Bevilacqua V, Martinovic M, Fabbris T, Sarnicola ML, Crosti M, Marongiu L, Granucci F, Notarbartolo S, Bandera A, Gori A, De Francesco R, Abrignani S, Caporali R, Grifantini R. Front Immunol. 2022 Jun 10;13:873195. doi: 10.3389/fimmu.2022.873195. eCollection 2022. PubMed
PEDOT:PSS in Solution Form Exhibits Strong Potential in Inhibiting SARS-CoV-2 Infection of the Host Cells by Targeting Viruses and Also the Host Cells. Hung JN, Kha Vo DN, Thanh Ho HP, Tsai MH. Biomacromolecules. 2022 Sep 12;23(9):3535-3548. doi: 10.1021/acs.biomac.2c00271. Epub 2022 Aug 2. PubMed
FASN inhibitor TVB-3166 prevents S-acylation of the spike protein of human coronaviruses. Mekhail K, Lee M, Sugiyama M, Astori A, St-Germain J, Latreille E, Khosraviani N, Wei K, Li Z, Rini J, Lee WL, Antonescu C, Raught B, Fairn GD. J Lipid Res. 2022 Sep;63(9):100256. doi: 10.1016/j.jlr.2022.100256. Epub 2022 Jul 31. PubMed
GDF15 and ACE2 stratify COVID-19 patients according to severity while ACE2 mutations increase infection susceptibility. Torrens-Mas M, Perello-Reus CM, Trias-Ferrer N, Ibarguen-Gonzalez L, Crespi C, Galmes-Panades AM, Navas-Enamorado C, Sanchez-Polo A, Pierola-Lopetegui J, Masmiquel L, Crespi LS, Barcelo C, Gonzalez-Freire M. Front Cell Infect Microbiol. 2022 Jul 22;12:942951. doi: 10.3389/fcimb.2022.942951. eCollection 2022. PubMed
Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. Duan LJ, Jiang WG, Wang ZY, Yao L, Zhu KL, Meng QC, Wang BS, Li LB, Wang GL, Ma MJ. iScience. 2022 Sep 16;25(9):104886. doi: 10.1016/j.isci.2022.104886. Epub 2022 Aug 9. PubMed
BSL2-compliant lethal mouse model of SARS-CoV-2 and variants of concern to evaluate therapeutics targeting the Spike protein. Manangeeswaran M, Ireland DDC, Thacker SG, Lee HN, Kelley-Baker L, Lewkowicz AP, Rothlauf PW, Cornejo Pontelli M, Bloyet LM, Eckhaus MA, Mendoza MI, Whelan S, Verthelyi D. Front Immunol. 2022 Jul 28;13:919815. doi: 10.3389/fimmu.2022.919815. eCollection 2022. PubMed
Apelin as a new therapeutic target for COVID-19 treatment. Park J, Park MY, Kim Y, Jun Y, Lee U, Oh CM. QJM. 2023 Mar 27;116(3):197-204. doi: 10.1093/qjmed/hcac229. PubMed
Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARS-CoV-2. Kim J, Jozic A, Mukherjee A, Nelson D, Chiem K, Khan MSR, Torrelles JB, Martinez-Sobrido L, Sahay G. Adv Sci (Weinh). 2022 Dec;9(35):e2202556. doi: 10.1002/advs.202202556. Epub 2022 Oct 10. PubMed
Astersaponin I from Aster koraiensis is a natural viral fusion blocker that inhibits the infection of SARS-CoV-2 variants and syncytium formation. Kim TY, Kim JY, Kwon HC, Jeon S, Lee SJ, Jung H, Kim S, Jang DS, Lee CJ. Antiviral Res. 2022 Dec;208:105428. doi: 10.1016/j.antiviral.2022.105428. Epub 2022 Oct 15. PubMed
Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion. Ho HPT, Vo DNK, Lin TY, Hung JN, Chiu YH, Tsai MH. Biomed Pharmacother. 2022 Nov;155:113766. doi: 10.1016/j.biopha.2022.113766. Epub 2022 Sep 28. PubMed
Metalloprotease-Dependent S2'-Activation Promotes Cell-Cell Fusion and Syncytiation of SARS-CoV-2. Harte JV, Wakerlin SL, Lindsay AJ, McCarthy JV, Coleman-Vaughan C. Viruses. 2022 Sep 21;14(10):2094. doi: 10.3390/v14102094. PubMed
Lancemaside A from Codonopsis lanceolata: Studies on Antiviral Activity and Mechanism of Action against SARS-CoV-2 and Its Variants of Concern. Kim TY, Jeon S, Ko M, Du YE, Son SR, Jang DS, Kim S, Lee CJ. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0120122. doi: 10.1128/aac.01201-22. Epub 2022 Nov 14. PubMed
SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly. Onnis A, Andreano E, Cassioli C, Finetti F, Della Bella C, Staufer O, Pantano E, Abbiento V, Marotta G, D'Elios MM, Rappuoli R, Baldari CT. J Exp Med. 2023 Feb 6;220(2):e20220906. doi: 10.1084/jem.20220906. Epub 2022 Nov 15. PubMed
Deep Evolutionary Forecasting identifies highly-mutated SARS-CoV-2 variants via functional sequence-landscape enumeration. Colom MS, Vucinic J, Adolf-Bryfogle J, Bowman JW, Verel S, Moczygemba I, Schiex T, Simoncini D, Bahl CD. Res Sq. 2022 Dec 2:rs.3.rs-2248327. doi: 10.21203/rs.3.rs-2248327/v1. Preprint. PubMed
Mapping of functional SARS-CoV-2 receptors in human lungs establishes differences in variant binding and SLC1A5 as a viral entry modulator of hACE2. Miluzio A, Cuomo A, Cordiglieri C, Donnici L, Pesce E, Bombaci M, Conti M, Fasciani A, Terracciano L, Manganaro L, Toccafondi M, Scagliola A, Oliveto S, Ricciardi S, Grifantini R, De Francesco R, Abrignani S, Manfrini N, Biffo S. EBioMedicine. 2023 Jan;87:104390. doi: 10.1016/j.ebiom.2022.104390. Epub 2022 Dec 28. PubMed
SARS-CoV-2 spike protein promotes inflammatory cytokine activation and aggravates rheumatoid arthritis. Lee AR, Woo JS, Lee SY, Lee YS, Jung J, Lee CR, Park SH, Cho ML. Cell Commun Signal. 2023 Mar 2;21(1):44. doi: 10.1186/s12964-023-01044-0. PubMed
Interferon-inducible phospholipids govern IFITM3-dependent endosomal antiviral immunity. Unali G, Crivicich G, Pagani I, Abou-Alezz M, Folchini F, Valeri E, Matafora V, Reisz JA, Giordano AMS, Cuccovillo I, Butta GM, Donnici L, D'Alessandro A, De Francesco R, Manganaro L, Cittaro D, Merelli I, Petrillo C, Bachi A, Vicenzi E, Kajaste-Rudnitski A. EMBO J. 2023 May 15;42(10):e112234. doi: 10.15252/embj.2022112234. Epub 2023 Mar 27. PubMed
Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants. Alcantara MC, Higuchi Y, Kirita Y, Matoba S, Hoshino A. Vaccines (Basel). 2023 Mar 22;11(3):711. doi: 10.3390/vaccines11030711. PubMed
SARS-CoV-2 infection and viral fusogens cause neuronal and glial fusion that compromises neuronal activity. Martinez-Marmol R, Giordano-Santini R, Kaulich E, Cho AN, Przybyla M, Riyadh MA, Robinson E, Chew KY, Amor R, Meunier FA, Balistreri G, Short KR, Ke YD, Ittner LM, Hilliard MA. Sci Adv. 2023 Jun 9;9(23):eadg2248. doi: 10.1126/sciadv.adg2248. Epub 2023 Jun 7. PubMed
Engineering an ACE2-Derived Fragment as a Decoy for Novel SARS-CoV-2 Virus. Renzi F, Seamann A, Ganguly K, Pandey K, Byrareddy SN, Batra S, Kumar S, Ghersi D. ACS Pharmacol Transl Sci. 2023 May 22;6(6):857-867. doi: 10.1021/acsptsci.2c00180. eCollection 2023 Jun 9. PubMed
Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants. Moriyama S, Anraku Y, Taminishi S, Adachi Y, Kuroda D, Kita S, Higuchi Y, Kirita Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y. Nat Commun. 2023 Jul 14;14(1):4198. doi: 10.1038/s41467-023-39890-8. PubMed
Convergent activation of two-pore channels mediated by the NAADP-binding proteins JPT2 and LSM12. Gunaratne GS, Brailoiu E, Kumar S, Yuan Y, Slama JT, Walseth TF, Patel S, Marchant JS. Sci Signal. 2023 Aug 22;16(799):eadg0485. doi: 10.1126/scisignal.adg0485. Epub 2023 Aug 22. PubMed
Competition for calnexin binding regulates secretion and turnover of misfolded GPI-anchored proteins. Cheatham AM, Sharma NR, Satpute-Krishnan P. J Cell Biol. 2023 Oct 2;222(10):e202108160. doi: 10.1083/jcb.202108160. Epub 2023 Sep 13. PubMed
The Apolipoprotein E neutralizing antibody inhibits SARS-CoV-2 infection by blocking cellular entry of lipoviral particles. Cui Q, Jeyachandran AV, Garcia G, Qin C, Zhou Y, Zhang M, Wang C, Sun G, Liu W, Zhou T, Feng L, Palmer C, Li Z, Aziz A, Gomperts BN, Feng P, Arumugaswami V, Shi Y. MedComm (2020). 2023 Oct 10;4(5):e400. doi: 10.1002/mco2.400. eCollection 2023 Oct. PubMed
SARS-CoV-2 spike protein accelerates systemic sclerosis by increasing inflammatory cytokines, Th17 cells, and fibrosis. Jeong HY, Park JS, Woo JS, Lee KH, Choi JW, Kang HY, Na HS, Lee YS, Um IG, Park SH, Cho ML. J Inflamm (Lond). 2023 Dec 21;20(1):46. doi: 10.1186/s12950-023-00362-x. PubMed

If you have published an article using this material, please email us at to have your article added to this page.